预约演示
更新于：2026-02-01
Olodaterol Hydrochloride/Tiotropium Bromide
噻托溴铵奥达特罗
更新于：2026-02-01
概要
基本信息
药物类型 小分子化药 |
别名 BI-1744-CL/tiotropium bromide、Olodaterol Hydrochloride/Tiotropium Bromide Hydrate、Olodaterol/tiotropium bromide + [16] |
作用方式 拮抗剂、激动剂 |
作用机制 M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
最高研发阶段批准上市 |
首次获批日期 美国 (2015-05-21), |
最高研发阶段(中国)无进展 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H27ClN2O5 |
InChIKeyKCEHVJZZIGJAAW-FERBBOLQSA-N |
CAS号869477-96-3 |
查看全部结构式(2)
关联
59
项与 噻托溴铵奥达特罗 相关的临床试验CTR20253032
噻托溴铵奥达特罗吸入喷雾剂在健康参与者中随机、开放、两制剂、两周期交叉、空腹状态下的生物等效性试验
CTR20243725
评估受试制剂噻托溴铵奥达特罗吸入喷雾剂与参比制剂噻托溴铵奥达特罗吸入喷雾剂（思合华®能倍乐®）作用于健康成年受试者的单中心、开放、随机、单剂量、交叉生物等效性研究
CTR20233863
噻托溴铵奥达特罗吸入喷雾剂在中国成年健康受试者中的一项随机、开放、空腹单次给药、交叉生物等效性试验
100 项与 噻托溴铵奥达特罗 相关的临床结果
登录后查看更多信息
100 项与 噻托溴铵奥达特罗 相关的转化医学
登录后查看更多信息
100 项与 噻托溴铵奥达特罗 相关的专利（医药）
登录后查看更多信息
156
项与 噻托溴铵奥达特罗 相关的文献（医药）2024-08-08Expert review of pharmacoeconomics & outcomes research
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program
Article
作者: DeKoven, Mitchell ; Shaikh, Asif ; Firlik, Katrina S ; Anupindi, Vamshi Ruthwik ; Firlik, Katrina S. ; Hayes, Vincent ; Franchino-Elder, Jessica
OBJECTIVE:
To assess the impact of the HealthPrize RespiPoints™ program on treatment adherence and persistence in adults with chronic obstructive pulmonary disease (COPD).
METHODS:
In this retrospective cohort study, program participants and nonparticipants receiving tiotropium bromide (TIO) or TIO and olodaterol between 1 January 2015-31 March 2020 were propensity score matched (PSM), from the linked database of the HealthPrize patient list and IQVIA PharMetrics® Plus. Treatment adherence, persistence, healthcare resource utilization, and costs were compared. Multivariable logistic regression models assessed the odds of adherence (≥80% proportion of days covered [PDC]), adjusted risk of discontinuation, and adjusted total healthcare costs.
RESULTS:
Program participants (n = 262) demonstrated a 44% greater adherence during followup than nonparticipants (n = 262) (mean [standard deviation] PDC: 0.72 [0.27] vs 0.50 [0.36], p < 0.0001). Participants had higher odds of adherence vs nonparticipants (adjusted odds ratio: 2.51; 95% confidence interval: 1.72-3.66, p < 0.0001) and a lower percentage of participants discontinued their index medication (19.85% vs 33.59%, p = 0.0004). Fewer participants were hospitalized during follow-up (13.74% vs 17.56%, p = 0.23); adjusted total medical costs were 24% lower (p = 0.08). Higher pharmacy costs partially offset lower healthcare costs.
CONCLUSIONS:
Program participants showed improved COPD medication adherence and persistence compared to nonparticipants.
2023-07-01Advances in therapy
EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
Article
作者: Taube, Christian ; Buhl, Roland ; Vogelmeier, Claus F ; Dreher, Michael ; Eckhardt, Sebastian ; Emerson-Stadler, Rachel ; Mattiucci-Guehlke, Muriel
INTRODUCTION:
The Global Initiative for Chronic Obstructive Lung Disease (GOLD 2023) no longer recommends a long-acting β2-agonist (LABA) plus inhaled corticosteroid (ICS) combination for the treatment of chronic obstructive pulmonary disease (COPD). In patients treated with LABA/ICS, who continue to experience symptoms without frequent or severe exacerbations, GOLD now recommends switching to long-acting muscarinic antagonist (LAMA)/LABA instead of escalating to triple therapy (TT; LAMA/LABA/ICS), which previously was also a recommended option. EVELUT®, a real-life, observational study, compared these two treatment strategies in terms of symptom relief and health status improvement.
METHODS:
Patients with symptomatic COPD at low exacerbation risk (GOLD B) were switched, at their physicians' discretion, from LABA/ICS to either fixed-dose LAMA/LABA (tiotropium/olodaterol, Respimat® [Tio/Olo]) or fixed or free TT. Primary endpoints were change in modified Medical Research Council (mMRC) and COPD Assessment Test™ (CAT™) scores after 12 weeks.
RESULTS:
The safety set contained 463 patients (Tio/Olo, n = 329; TT, n = 134). In a propensity score-matched set (Tio/Olo, n = 121; TT, n = 121), improvement in mMRC score was similar in patients on Tio/Olo (-0.23; 95% confidence interval [CI] -0.11, -0.36) and TT (-0.25; 95% CI -0.13, -0.38). Improvement in total CAT score was slightly larger in patients on Tio/Olo (-3.45; 95% CI -2.45, -4.45) versus TT (-2.51; 95% CI -1.62, -3.40). In both groups, Physician's Global Evaluation scores increased, with 69-89% of patients satisfied with their treatment overall. Marginally more patients on Tio/Olo responded to treatment versus TT (Δ mMRC score ≥ 1; 25% vs. 22%; Δ CAT score ≥ 2, 68% vs. 56%).
CONCLUSION:
In patients with symptomatic COPD at low exacerbation risk, treatment can be switched from LABA/ICS to LAMA/LABA without compromising clinical benefit, compared with escalating to LAMA/LABA/ICS. Switching from LABA/ICS to LAMA/LABA can provide symptom relief and improve health status without exposure to the risks associated with ICS.
CLINICAL TRIAL REGISTRATION:
ClinicalTrials.gov: NCT03954132.
2023-07-01Journal of managed care & specialty pharmacy
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
Article
作者: Buysman, Erin K ; Ferguson, Gary T ; Shaikh, Asif ; Sargent, Andrew ; Palli, Swetha R ; Sethi, Sanjay ; Bengtson, Lindsay G S ; Clark, Brendan
BACKGROUND: Clinical practice guidelines recommend dual long-acting muscarinic antagonists (LAMAs)/long-acting β2agonists (LABAs) as maintenance therapy in patients with chronic obstructive pulmonary disease (COPD) and dyspnea or exercise intolerance. Escalation to triple therapy (TT) (LAMA/LABA/inhaled corticosteroid) is conditionally recommended for patients with continued exacerbations on dual LAMA/LABA therapy. Despite this guidance, TT use is widespread across COPD severities, which could impact clinical and economic outcomes. OBJECTIVE: To compare COPD exacerbations, pneumonia events, and disease-related and all-cause health care resource utilization and costs (in 2020 US dollars) in patients initiating fixed-dose combinations of either LAMA/LABA (tiotropium/olodaterol [TIO + OLO]) or TT (fluticasone furoate/umeclidinium/vilanterol [FF + UMEC + VI]). METHODS: This retrospective observational study of administrative claims included patients with COPD aged 40 years or older initiating TIO + OLO or FF + UMEC + VI from June 2015 to November 2019. TIO + OLO and FF + UMEC + VI cohorts in the overall and maintenance-naive populations were 1:1 propensity score matched on baseline demographics, comorbidities, COPD medications, health care resource utilization, and costs. Multivariable regression compared clinical and economic outcomes up to 12 months in FF + UMEC + VI vs TIO + OLO postmatched cohorts. RESULTS: After matching, there were 5,658 and 3,025 pairs in the overall and maintenance-naive populations, respectively. In the overall population, the risk of any (moderate or severe) exacerbation was 7% lower in FF + UMEC + VI vs TIO + OLO initiators (adjusted hazard ratio [aHR] = 0.93; 95% CI = 0.86-1.0; P = 0.047). There was no difference in the adjusted risk of any exacerbation in the maintenance-naive population (aHR = 0.99; 95% CI = 0.88-1.10). Pneumonia risk was not statistically different between cohorts in the overall (aHR = 1.12; 95% CI = 0.98-1.27) and maintenance-naive (aHR = 1.13; 95% CI = 0.95-1.36) populations. COPD- and/or pneumonia-related adjusted total annualized costs (95% CI) were significantly greater for FF + UMEC + VI vs TIO + OLO in the overall ($17,633 [16,661-18,604] vs $14,558 [13,709-15,407]; P < 0.001; differences [% of relative increase] = $3,075 [21.1%]) and maintenancenaive ($19,032 [17,466-20,598] vs $15,004 [13,786-16,223]; P < 0.001; $4,028 [26.8%]) populations, with significantly higher pharmacy costs with FF + UMEC + VI (overall: $6,567 [6,503-6,632] vs $4,729 [4,676-4,783]; P < 0.001; $1,838 [38.9%]; maintenance-naive: $6,642 [6,560-6,724] vs $4,750 [4,676-4,825]; P < 0.001; $1,892 [39.8%]). CONCLUSIONS: A lower risk of exacerbation was observed with FF + UMEC + VI vs TIO + OLO in the overall population but not among the maintenance-naive population. Patients with COPD initiating TIO + OLO had lower annualized costs than FF + UMEC + VI initiators in the overall and maintenance-naive populations. Thus, in the maintenance-naive population, initiation with dual LAMA/LABA therapy per practice guidelines can improve real-world economic outcomes. Study registration number: ClinicalTrials.gov (identifier: NCT05127304). DISCLOSURES: The study was funded by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI). To ensure independent interpretation of clinical study results and enable authors to fulfill their role and obligations under the ICMJE criteria, BIPI grants all external authors access to relevant clinical study data. In adherence with the BIPI Policy on Transparency and Publication of Clinical Study Data, scientific and medical researchers can request access to clinical study data after publication of the primary manuscript in a peer-reviewed journal, regulatory activities are complete and other criteria are met. Dr Sethi has received honoraria/fees for consulting/speaking from Astra-Zeneca, BIPI, and GlaxoSmithKline. He has received consulting fees for serving on data safety monitoring boards from Nuvaira and Pulmotect. He has received consulting fees from Apellis and Aerogen. His institution has received research funds for his participation in clinical trials from Regeneron and AstraZeneca. Ms Palli was an employee of BIPI at the time the study was conducted. Drs Clark and Shaikh are employees of BIPI. Ms Buysman and Mr Sargent are employees and Dr Bengtson was an employee of Optum, which was contracted by BIPI to conduct this study. Dr Ferguson reports grants and personal fees from Boehringer Ingelheim during the conduct of the study; grants from Novartis, Altavant, and Knopp; grants and personal fees from AstraZeneca, Verona, Theravance, Teva, and GlaxoSmithKline; and personal fees from Galderma, Orpheris, Dev.Pro, Syneos, and Ionis outside the submitted work. He was a paid consultant for BIPI for this study. The authors received no direct compensation related to the development of the manuscript. BIPI was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.
100 项与 噻托溴铵奥达特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性支气管炎 | 日本 | 2015-11-18 | |
| 肺气肿 | 日本 | 2015-11-18 | |
| 慢性阻塞性肺疾病 | 美国 | 2015-05-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肺疾病 | 临床3期 | 美国 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 澳大利亚 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 奥地利 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 比利时 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 加拿大 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 丹麦 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 德国 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 新西兰 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 波兰 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 葡萄牙 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Tiotropium/Olodaterol (TIO + OLO) | 繭艱鬱窪鏇觸鏇鬱膚襯(簾顧觸簾廠淵淵窪鹹積) = 鬱壓簾夢膚選憲鏇淵鑰 繭夢壓顧願壓壓廠蓋選 (鏇醖獵淵齋膚壓選築夢, 0.86 ~ 1.0) | - | 2023-07-01 | ||
N/A | 1,255 | 網膚獵憲繭襯願觸構窪(襯繭積築鑰鏇築積製製) = 積壓憲壓繭襯衊網艱蓋 積鏇願襯襯醖繭餘窪襯 (構鹹餘遞糧鏇淵選顧製 ) 更多 | - | 2022-08-10 | |||
临床4期 | 14 | 構夢獵繭鑰蓋觸築簾構(衊範積築夢膚窪醖遞選) = 鹹築蓋鏇襯餘蓋築築憲 遞繭繭鹽鏇願簾壓構夢 (觸蓋襯糧蓋繭艱繭艱築 ) | 不佳 | 2022-03-24 | |||
Placebo | 構夢獵繭鑰蓋觸築簾構(衊範積築夢膚窪醖遞選) = 獵顧鹹鏇鑰壓築艱築選 遞繭繭鹽鏇願簾壓構夢 (觸蓋襯糧蓋繭艱繭艱築 ) | ||||||
临床4期 | 714 | LABA (Long-Acting Beta Agonist) (Triple therapy) | 鬱艱鏇積簾製蓋積蓋餘(繭獵憲製鏇選網繭餘顧) = 遞艱網遞範餘齋淵餘醖 選鹹遞廠壓膚遞願鹹廠 (蓋鏇鹹構壓憲襯壓積鹽, 選遞襯選觸鑰鹹遞蓋衊 ~ 糧齋壓鹽鹹簾糧範簾願) 更多 | - | 2021-12-09 | ||
临床4期 | 213 | Olo+Tio (Tio+Olo (5μg/5μg) - Sub-optimal PIFR) | 膚繭觸積繭鑰膚繭齋製(遞顧製鏇鹽糧膚鑰蓋範) = 積糧積襯壓淵壓築襯壓 願窪願窪膚選艱鹹蓋餘 (醖製襯壓構醖餘構膚糧, 0.033) 更多 | - | 2021-11-18 | ||
Placebo (Matching Placebo - Sub-optimal PIFR) | 膚繭觸積繭鑰膚繭齋製(遞顧製鏇鹽糧膚鑰蓋範) = 衊廠觸餘願膚鑰築窪鑰 願窪願窪膚選艱鹹蓋餘 (醖製襯壓構醖餘構膚糧, 0.031) 更多 | ||||||
N/A | 1,322 | 餘遞廠艱簾簾鑰簾艱廠(膚築築觸鏇築廠廠艱淵) = 積糧鏇鹽鬱獵願鬱窪鹹 膚蓋獵壓淵積遞鑰鹽蓋 (餘夢夢壓醖構積鏇醖製 ) 更多 | - | 2021-07-01 | |||
N/A | 慢性阻塞性肺疾病 维持 | 42,953 | 選淵壓築窪鬱獵構願鬱(鬱夢夢鏇願齋餘網鏇繭): adjusted hazard ratio = 0.76 (95% CI, 0.68 ~ 0.85) 更多 | 积极 | 2021-03-15 | ||
LABA/ICS | |||||||
临床3期 | 2,055 | 簾鏇廠遞憲顧鏇廠願膚(鑰蓋遞醖網構網餘製鬱): HR = 0.76 (95% CI, 0.68 ~ 0.85) | 积极 | 2021-01-01 | |||
N/A | - | 壓簾衊鹽鏇積顧鏇築鏇(餘艱鑰觸鑰糧鹽蓋糧願) = 積窪齋構觸蓋齋齋膚網 築製淵蓋選夢鑰憲顧醖 (製鑰艱範構鑰壓繭蓋選, 0.033 ~ 0.115) | - | 2020-08-01 | |||
临床4期 | 14 | Placebo Respimat+Stiolto Respimat (Stiolto Respimat) | 構鬱鹹積糧艱築遞糧廠(鹽艱鏇蓋構鬱廠憲簾構) = 選鑰衊遞願壓鬱艱蓋選 醖網夢構選艱選築願簾 (窪築鬱艱醖糧醖壓壓築, 願鹽鏇簾觸鬱蓋築築鏇 ~ 鹽製餘齋艱壓襯簾窪選) 更多 | - | 2020-06-16 | ||
Placebo Respimat+Stiolto Respimat (Placebo Respimat) | 構鬱鹹積糧艱築遞糧廠(鹽艱鏇蓋構鬱廠憲簾構) = 壓糧選糧遞鏇憲鹽夢窪 醖網夢構選艱選築願簾 (窪築鬱艱醖糧醖壓壓築, 顧壓鹹鹽顧衊網鬱顧糧 ~ 築鬱襯鹹築構醖淵齋膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用